Citadel Advisors’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
Citadel Advisors's KYMR Position: Q3 2026 in Review
Citadel Advisors sold out of Kymera Therapeutics (KYMR) in Q3 2026, closing a stake of 111,555 shares — an estimated $12.8M sold.
Citadel Advisors first reported a position in KYMR in Q1 2021 and held it in 21 quarters. The position peaked at $22.6M in Q2 2025. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- Citadel Advisors reported no remaining Kymera Therapeutics position as of Q3 2026 after selling out during the quarter.
- Citadel Advisors sold 111,555 Kymera Therapeutics shares in Q3 2026, an estimated $12.8M.
- Citadel Advisors first reported a position in Kymera Therapeutics in Q1 2021 and held it in 21 quarters.
- Citadel Advisors's Kymera Therapeutics position peaked at $22.6M in Q2 2025.
- 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.